Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Anim Hosp Assoc ; 51(6): 365-71, 2015.
Article in English | MEDLINE | ID: mdl-26535454

ABSTRACT

Staphylococcus pseudintermedius is the most prevalent coagulase-positive Staphylococcus inhabitant of the skin and mucosa of dogs and cats, causing skin and soft tissue infections in these animals. In this study, coagulase-positive Staphylococcus species were isolated from companion animals, veterinary professionals, and objects from a clinical veterinary environment by using two particular culture media, Baird-Parker RPF agar and CHROMagar Staph aureus. Different morphology features of colonies on the media allowed the identification of the species, which was confirmed by performing a multiplex polymerase chain reaction (PCR). Among 23 animals, 15 (65.2%) harbored coagulase-positive Staphylococcus, being 12 Staphylococcus pseudintermedius carriers. Four out of 12 were methicillin-resistant S. pseudintermedius (MRSP). All veterinary professionals had coagulase-positive Staphylococcus (CoPS) species on their hands and two out of nine objects sampled harbored MRSP. The antimicrobial-resistance pattern was achieved for all isolates, revealing the presence of many multidrug-resistant CoPS, particularly S. pseudintermedius . The combined analysis of the antimicrobial-resistance patterns shown by the isolates led to the hypothesis that there is a possible crosscontamination and dissemination of S. aureus and S. pseudintermedius species between the three types of carriers sampled in this study that could facilitate the spread of the methicillin-resistance phenotype.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cat Diseases/microbiology , Dog Diseases/microbiology , Drug Resistance, Bacterial , Staphylococcal Infections/veterinary , Staphylococcus/classification , Animals , Bacteriological Techniques , Carrier State/epidemiology , Carrier State/microbiology , Carrier State/veterinary , Cats , Coagulase/metabolism , Dogs , Environmental Microbiology , Hospitals, Animal , Humans , Prevalence , Staphylococcal Infections/epidemiology , Staphylococcal Infections/microbiology , Staphylococcus/drug effects , Staphylococcus/enzymology
2.
J Clin Microbiol ; 52(12): 4325-9, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25320229

ABSTRACT

We developed a new transport medium (GESA--Helicobacter pylori transport medium [publication no. WO/2014/019696, patent pending no. PCT/EP2013/002292; Liofilchem s.r.l., Roseto degli Abruzzi, Teramo, Italy]) for recovery of Helicobacter pylori from gastric biopsy samples. GESA transport medium, in a semisolid state, provides the optimal conditions for maintaining the viability of the microorganism over time. The efficacy of the transport medium was assessed through in vitro and ex vivo experiments. We were able to recover different suspensions of H. pylori ATCC 43629 and H. pylori 13 A in GESA transport medium stored at 4 °C for up to 10 days. In particular, with a starting inoculum of ∼ 10(5) CFU, after 7 days of storage, 150 ± 25 CFU and 40 ± 7 CFU of the reference and clinical strains were detected, respectively. H. pylori colonies were isolated from gastric specimens taken from both the antrum and the fundus in 68 (90.66%) of 75 urea breath test (UBT)-positive patients. Moreover, GESA transport medium allowed the recovery and isolation of H. pylori colonies from additional biopsy samples from 13 of the 75 detected subjects at up to 10 days of biopsy sample storage at 4 °C. Finally, GESA transport medium preserved its characteristics when stored at 4°C for 1 year from its preparation, thus allowing good recovery of H. pylori. GESA transport medium can be considered a standardized transport medium with high performance that optimizes the recovery rate of H. pylori grown by culture.


Subject(s)
Bacteriological Techniques/methods , Biopsy , Helicobacter Infections/diagnosis , Helicobacter pylori/isolation & purification , Specimen Handling/methods , Gastric Mucosa/microbiology , Helicobacter pylori/physiology , Humans , Italy , Microbial Viability , Temperature , Time Factors
3.
Int J Mol Sci ; 12(8): 5039-51, 2011.
Article in English | MEDLINE | ID: mdl-21954343

ABSTRACT

The ability to form biofilms contributes significantly to the pathogenesis of many microbial infections, including a variety of ocular diseases often associated with the biofilm formation on foreign materials. Carvacrol (Car.) is an important component of essential oils and recently has attracted much attention pursuant to its ability to promote microbial biofilm disruption. In the present study Car. has been encapsulated in poly(dl-lactide-co-glycolide (PLGA) nanocapsules in order to obtain a suitable drug delivery system that could represent a starting point for developing new therapeutic strategies against biofilm-associated infections, such as improving the drug effect by associating an antimicrobial agent with a biofilm viscoelasticity modifier.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Biofilms/drug effects , Lactic Acid/chemistry , Monoterpenes/administration & dosage , Nanoparticles/chemistry , Polyglycolic Acid/chemistry , Anti-Bacterial Agents/chemistry , Chemistry, Pharmaceutical , Cymenes , Drug Delivery Systems , Humans , Kinetics , Monoterpenes/chemistry , Nanoparticles/ultrastructure , Polylactic Acid-Polyglycolic Acid Copolymer , Staphylococcus epidermidis/drug effects , Staphylococcus epidermidis/physiology
SELECTION OF CITATIONS
SEARCH DETAIL